BACKGROUND
The introduction of targeted antiangiogenic agents has revolutionized the treatment of metastatic clear cell renal cancer (mRCC) [1] [2] [3] [4] . Sunitinib prolongs survival and is established as first line therapy in metastatic disease [1, 2] . The majority of patients treated with sunitinib initially obtain a clinical benefit, however acquired resistance occurs and is associated with a poor outcome [3] . Traditional methods of identifying patients who benefit from therapy, such as radiological response by RECIST criteria, have not proved as helpful in renal cancer [5] . Correlative biomarkers to identify subsets of patients who benefit from sunitinib therapy are required.
Positron emission tomography (PET), using F-18-fluorodeoxyglucose (FDG), is useful as a diagnostic tool in some tumors as lung cancer, however results in renal cancer have been less helpful [6, 7] . Several studies have also shown that changes in tumor metabolism, measured by FDG-PET/CT, occurs early in the course of systemic therapy and may predict outcome [8, 9] . Indeed metabolic responses, defined as a >20% reduction in the standard uptake variable (SUV), predict clinical benefit from sunitinib in gastrointestinal stromal tumors [10] . However, relatively little is known about the role of FDG-PET/CT for treatment monitoring in renal cancer. Preliminary data suggests that targeted therapies, such as sunitinib, can result in a reduction in tumor metabolic activity in mRCC, but its role as a correlative biomarker in sunitinib treated patients has not been evaluated [11] .
In this prospective study we test the hypothesis that metabolic response assessed by FDG-PET/CT, defined as a >20% reduction in SUV, correlates with outcome in untreated patients with mRCC treated with sunitinib. FDG-PET/CT was performed before, after 4 and after 16 weeks of sunitinib treatment, to determine if the timing of imaging influenced the results. The 4 week time point was chosen because FDG-PET/CT is prognostically discriminatory with sunitinib in other tumour types at this time 
METHODS

Study design and patients selection
Forty four patients with newly diagnosed untreated metastatic clear cell renal cancer participated in a prospective phase II multi-centre trial using sunitinib (SUMR NCT01024205) [12] . The primary endpoint of the SUMR trial was to assess the clinical benefit of upfront sunitinib in metastatic clear cell renal cancer in MSKCC intermediate and poor risk patients who had not had a nephrectomy. Analysis of progression free survival (PFS) was performed using RECIST v1.1. The primary endpoint of SUMR was to show a clinical benefit (CR, PR or SD by RECIST v1.1) in 70% or more patients after 16 weeks of sunitinib (which was achieved: clinical benefit= 86%). Outcome data was available for both PFS and overall survival (OS) for this study.
All patients participating in the SUMR trial also participated in a FDG-PET/CT imaging study. The sequential FDG-PET imaging aspect of the study was an established secondary endpoint of the trial. This endpoint was to correlate FDG PET-CT response (20% reduction in SUVmax) at 4 and 16 weeks with outcome (PFS and OS). Other exploratory endpoints of the imaging aspects of this study included correlating SUVmax and number of FDG-PET positive lesions at baseline with outcome (PFS and OS). We also compared SUV levels in the metastatic sites and primary renal tumor as an exploratory endpoint. FDG-PET/CT scans results had no influence on treatment decisions.
Statistics
The OS and PFS were analyzed using the Kaplan-Meier method. Comparison of groups was performed using the log rank test. Univariate and multivariate analysis was performed to identify independent prognostic factors associated with a poor outcome.
Factors included in this model included age, gender, Heng risk factors, tumor grade, best response to therapy and number of metastatic sites. Correlation coefficients were used to compare SUV uptake in the metastatic sites and kidney tumors. Cutpoint analysis was performed as part of the exploratory analysis to identify levels of most significance. Statistical analysis was performed using SPSS and STATA 10 software packages. This study was reviewed and approved by the internal review board and had external ethical approval by an appropriate ethics committee.
Treatment
Sunitinib was given for 4 weeks at 50mg orally followed by a 2 week interval, in repeat cycles. Doses were reduced to 37.5mg and subsequently to 25mg in the face of toxicity (grade 3 or more). Second line therapy was not widely available during this period in the UK and only 3 patients received further targeted therapy.
FDG-PET/CT Imaging
A FDG-PET/CT was performed (0-14 days [median 1 days]) before sunitinib therapy.
The second scan was performed 2 to 5 days (median 2 days) after the last dose of drug on cycle 1 (week 4). The third scan was performed 1-6 days (median 2 days) after the last dose of drug on cycle 3 (week 16).
Images were acquired 60 minutes following injection of 400 MBq of 
Response Assessment
FDG avid tumor lesions were identified at baseline. The most FDG avid lesion was selected as the target lesion. This was followed prospectively for changes in tumor metabolic activity by measuring standardized uptake values (SUV). The percentage change in SUV (∆SUV%) was calculated between baseline and subsequent FDG-PET/CT at 4 and 16 weeks. PET response was stratified by the metabolic response criteria using a >20% reduction in SUV [13] . We chose this widely used threshold Best response evaluation (by CT RECIST v1.1) showed a partial response in 6 patients (14%), stable disease in 30 (68%) and progressive disease in 8 patients (18%).
Treatment associated toxicity (grade 3 or more) occurred in 24 patients (54%) and required a dose reduction. Toxicity was in line with that previously described with sunitinib.
The progression free and overall survival for all patients was 9.2 months (95%CI: 5.9-21.0 months) and 14.4 months (95%CI: 9.1-NA) respectively. Second line therapy was given to 3 patients (sorafenib n=1 and everolimus n=2). 
FDG-PET/CT at baseline
Forty-three patients (98%) had a positive FDG-PET/CT at baseline prior to starting sunitinib (table 2). The primary renal cancer was FDG avid in 40 (91%) patients and 39 (89%) had FDG avid metastatic sites. The SUVmax for all tumor sites ranged between <2.5 and 18.4 (median SUVmax 6.8). There was no difference in the level of FDG uptake observed between the primary tumor (median SUVmax 5.6; range <2. 5-18.4) and metastatic sites (median SUVmax 5.4; range <2.5-16.7). The commonest metabolically active metastatic sites were lung (n=25), lymph nodes (n=24), bone (n=12), adrenal (n=8) and liver (n=7). The sensitivity and specificity for FDG-PET/CT compared to contrast enhanced CT was 87% and 95% respectively. The median reduction in SUVmax for the primary tumor was 23% (range 67% reduction to 80% increase) and for metastatic sites was 14% (60% reduction to 31% increase).
Metabolic response was not associated with a prolonged PFS or OS in either the primary tumor or metastatic sites (p>0.05 for each). There was a positive correlation between metabolic response in the primary tumor and metastatic sites (p<0.001).
Responding patients with a high and low initial SUV were compared for outcome. The initial SUV (below median v.s above median) in PET responders had no effect on survival although the numbers were small (p>0.05). The observation that the timing of functional imaging is relevant in predicting outcome may explain why previous angiogenic imaging studies with DCE MRI and ultrasound in this field have been contradictory [14, 15] . Future work comparing FDG-PET/CT and dynamic contrast enhanced MRI/ultrasound at sequential time points would help clarify these issues. Ideally sequential biopsies, taken from multiple sites for molecular analysis at the same time as functional imaging would be invaluable although ethically challenging.
In contrast to our data, FDG-PET/CT responses in gastrointestinal stromal tumors at 4 weeks are prognostically significant. This underlines the inherent molecular differences between the two tumor types [10, 16, 17] .
FDG-PET has not been widely used in metastatic renal cancer as it was not initially thought to add to standard diagnostic procedures [18] . Our works shows that FDG-PET/CT at diagnosis has a relatively high sensitivity and specificity compared to previous smaller reports [7] . We speculate that this is because our series consisted of 
patients with widespread aggressive disease (compared to previous reports).
Nevertheless, for diagnostic purposes these results should be interpreted in conjunction with CT or MRI. Our results also show FDG-PET/CT gives additional prognostic information, in that high SUVmax and an increased number of PET positive lesions are both associated with a poor outcome in multivariate analysis. This information potentially helps further define a subgroup of patients with a poor outcome and could be the basis for clinical studies in the future [19] .
This work has a number of shortcomings. The phase II clinical study (SUMR), from which this work was derived, was powered to address the efficacy of upfront sunitinib (the primary endpoint) and therefore the prespecified sequential PET analysis, which was the focus of the translational aspect of the study, was exploratory in nature.
Nevertheless the sequential scans delivered significant findings which can be taken forward. Also, sequential PET scans were only preformed in patients who had not 
